The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Call for Applications: Mesothelioma Research Grants
The Mesothelioma Applied Research Foundation (Meso Foundation) is calling for applications for available mesothelioma research funding
The Meso Foundation (formerly known as MARF) is the non-profit dedicated to ending the suffering caused by mesothelioma. We are the international collaboration of patients and families, physicians, advocates, and researchers dedicated to eradicating the life-ending and vicious effects of mesothelioma. We believe in a cure for meso. In addition to raising awareness of the disease, advocating on behalf of the meso community, educating those newly diagnosed and providing support to those affected, we fund the most promising mesothelioma research projects through rigorous peer-review. To date we have received 520 proposals since 2000 of which 108 projects from six different countries were awarded over $10 million dollars.
The Meso Foundation’s research grant program offers grants for two years up to $50,000 per year. Eligible projects may relate to benchwork, translational or clinical research that is not presently funded and may be conducted through any not-for-profit academic, medical or research institution. We encourage all levels and degrees of scientists to apply.
Deadline for Letter of Intent: Aug. 26, 2019
Areas of Interest
Encouraged projects include, but are not limited to:
1. Strategies for early detection and prevention of mesothelioma
2. Definition of targetable differences between normal and transformed mesothelium and development of novel strategies for treatment taking advantage of these targets
3. Determination of clinical/molecular determinants for prognosis
4. Research in peritoneal mesothelioma – one grant in 2019 will go to peritoneal research
5. Therapeutic intervention, including but not limited to:
a. Immune Response Targeted Therapy
b. Novel chemotherapeutic compounds